BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 35978886)

  • 1. TAB2 Promotes the Biological Functions of Head and Neck Squamous Cell Carcinoma Cells via EMT and PI3K Pathway.
    Liu H; Zhang H; Fan H; Tang S; Weng J
    Dis Markers; 2022; 2022():1217918. PubMed ID: 35978886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of p21-activated kinase 4 in the progression of oral squamous cell carcinoma by targeting PI3K-AKT signaling pathway.
    Zhang L; Lin S; Zhang Z; Yan C; Liu F
    Clin Transl Oncol; 2023 Mar; 25(3):739-747. PubMed ID: 36593383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-186-5p inhibits the progression of oral squamous cell carcinoma by targeting ITGA6 to impair the activity of the PI3K/AKT pathway.
    Chen M; Zhang J
    J Oral Pathol Med; 2022 Apr; 51(4):322-331. PubMed ID: 35201653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PSMC2 knockdown inhibits the progression of oral squamous cell carcinoma by promoting apoptosis via PI3K/Akt pathway.
    Wang Z; Xiong H; Zuo Y; Hu S; Zhu C; Min A
    Cell Cycle; 2022 Mar; 21(5):477-488. PubMed ID: 34979867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BST2 regulated by the transcription factor STAT1 can promote metastasis, invasion and proliferation of oral squamous cell carcinoma via the AKT/ERK1/2 signaling pathway.
    Shan F; Shen S; Wang X; Chen G
    Int J Oncol; 2023 Apr; 62(4):. PubMed ID: 36929425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spindle and kinetochore-associated complex 3 promotes cell growth via the PI3K/AKT/GSK3β and PI3K/AKT/FOXO1 pathways and is a potential prognostic biomarker for oral squamous cell carcinoma.
    Xu H; Chen G; Niu Q; Song K; Feng Z; Han Z
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2022 Nov; 134(5):599-614. PubMed ID: 36123287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RELA promotes the progression of oral squamous cell carcinoma via TFAP2A-Wnt/β-catenin signaling.
    Yang K; Zhao J; Liu S; Man S
    Mol Carcinog; 2023 May; 62(5):641-651. PubMed ID: 36789977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated Expression of Zinc Finger Protein 703 Promotes Cell Proliferation and Metastasis through PI3K/AKT/GSK-3β Signalling in Oral Squamous Cell Carcinoma.
    Wang H; Deng X; Zhang J; Ou Z; Mai J; Ding S; Huo S
    Cell Physiol Biochem; 2017; 44(3):920-934. PubMed ID: 29176314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. POLE2 Regulates Apoptosis of Oral Squamous Cell Carcinoma Cells through the PI3K/AKT Signaling Pathway.
    Sun MY; Wang L; Shen ZY
    Curr Med Sci; 2023 Dec; 43(6):1162-1172. PubMed ID: 38079056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of phosphoprotein associated with glycosphingolipid-enriched microdomains 1 (PAG1) in regulating the progression of oral squamous cell carcinoma.
    Sun Y; Yang X; Guan S; Ma T; Jiang Z; Gao M; Xu Y; Cong B
    Arch Oral Biol; 2023 Dec; 156():105810. PubMed ID: 37852106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CircZDBF2 up-regulates RNF145 by ceRNA model and recruits CEBPB to accelerate oral squamous cell carcinoma progression via NFκB signaling pathway.
    Rong L; Chen B; Liu K; Liu B; He X; Liu J; Li J; He M; Zhu L; Liu K; Shi X; Shuai Y; Jin L
    J Transl Med; 2022 Apr; 20(1):148. PubMed ID: 35365168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Knockdown of lncRNA IGF2BP2-AS1 inhibits proliferation and migration of oral squamous cell carcinoma cells via the Wnt/β-catenin pathway.
    Tong S; Wang X; Guo X; Lu Z
    J Oral Pathol Med; 2022 Mar; 51(3):272-280. PubMed ID: 34637162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-654-5p Targets GRAP to Promote Proliferation, Metastasis, and Chemoresistance of Oral Squamous Cell Carcinoma Through Ras/MAPK Signaling.
    Lu M; Wang C; Chen W; Mao C; Wang J
    DNA Cell Biol; 2018 Apr; 37(4):381-388. PubMed ID: 29364705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. As a Novel Tumor Suppressor, LHPP Promotes Apoptosis by Inhibiting the PI3K/AKT Signaling Pathway in Oral Squamous Cell Carcinoma.
    Liu S; Gao W; Lu Y; Zhou Q; Su R; Hasegawa T; Du J; Li M
    Int J Biol Sci; 2022; 18(2):491-506. PubMed ID: 35002505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunity-related long noncoding RNA WDFY3-AS2 inhibited cell proliferation and metastasis through Wnt/β-catenin signaling in oral squamous cell carcinoma.
    Lin X; Ding JM; Zheng XZ; Chen JG
    Arch Oral Biol; 2023 Mar; 147():105625. PubMed ID: 36657277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CLSPN actives Wnt/β-catenin signaling to facilitate glycolysis and cell proliferation in oral squamous cell carcinoma.
    Hou Z; Wu C; Tang J; Liu S; Li L
    Exp Cell Res; 2024 Feb; 435(2):113935. PubMed ID: 38237848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The circEPSTI1/mir-942-5p/LTBP2 axis regulates the progression of OSCC in the background of OSF via EMT and the PI3K/Akt/mTOR pathway.
    Wang J; Jiang C; Li N; Wang F; Xu Y; Shen Z; Yang L; Li Z; He C
    Cell Death Dis; 2020 Aug; 11(8):682. PubMed ID: 32826876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HMG20A was identified as a key enhancer driver associated with DNA damage repair in oral squamous cell carcinomas.
    Na L; Meijie Z; Wenjing Z; Bing Z; Yanhao D; Shanshan L; Yongle Q
    BMC Oral Health; 2022 Nov; 22(1):473. PubMed ID: 36335317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-6 mediated inflammasome activation promotes oral squamous cell carcinoma progression via JAK2/STAT3/Sox4/NLRP3 signaling pathway.
    Xiao L; Li X; Cao P; Fei W; Zhou H; Tang N; Liu Y
    J Exp Clin Cancer Res; 2022 May; 41(1):166. PubMed ID: 35513871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitor of Growth 4 (ING4) Plays a Tumor-repressing Role in Oral Squamous Cell Carcinoma via Nuclear Factor Kappa-B (NF-kB)/DNA Methyltransferase 1 (DNMT1) Axis-mediated Regulation of Aldehyde Dehydrogenase 1A2 (ALDH1A2).
    Cui Z; Sun S; Li J; Li J; Sha T; He J; Zuo L
    Curr Cancer Drug Targets; 2022; 22(9):771-783. PubMed ID: 35388759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.